0 CHECKOUT

Chlamydia Infections - Pipeline Review, H1 2015

  • ID: 3266308
  • April 2015
  • 76 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Abera Bioscience AB
  • Big DNA Ltd.
  • CEL-SCI Corporation
  • Genocea Biosciences, Inc.
  • Merck & Co., Inc.
  • Osel Inc.
  • MORE

Chlamydia Infections - Pipeline Review, H1 2015

Summary

This, ‘Chlamydia Infections - Pipeline Review, H1 2015’, provides an overview of the Chlamydia Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chlamydia Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chlamydia Infections and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abera Bioscience AB
  • Big DNA Ltd.
  • CEL-SCI Corporation
  • Genocea Biosciences, Inc.
  • Merck & Co., Inc.
  • Osel Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Chlamydia Infections Overview
Therapeutics Development
Pipeline Products for Chlamydia Infections - Overview
Pipeline Products for Chlamydia Infections - Comparative Analysis
Chlamydia Infections - Therapeutics under Development by Companies
Chlamydia Infections - Therapeutics under Investigation by Universities/Institutes
Chlamydia Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Chlamydia Infections - Products under Development by Companies
Chlamydia Infections - Products under Investigation by Universities/Institutes
Chlamydia Infections - Companies Involved in Therapeutics Development
Abera Bioscience AB
Adamis Pharmaceuticals Corporation
Big DNA Ltd.
CEL-SCI Corporation
Foamix Pharmaceuticals Ltd.
Genocea Biosciences, Inc.
Merck & Co., Inc.
Osel Inc.
Prokarium Ltd.
QureTech Bio AB
Chlamydia Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Ab-03 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
acALY-18 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BDNA-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biologic for Infectious Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-31G - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia trachomatis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
chlamydia vaccines - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Block Virulence for Chlamydia Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GEN-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
minocycline Gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptides to Inhibit CPAF for Chlamydia Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Chlamydophila Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
solithromycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VNI-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chlamydia Infections - Recent Pipeline Updates
Chlamydia Infections - Dormant Projects
Chlamydia Infections - Product Development Milestones
Featured News & Press Releases
Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection
Jul 20, 2011: Newly Designed Molecule Blocks Chlamydia Bacteria
Apr 26, 2010: Foamix is granted a fourth U.S. patent for OilGel, directed to pharmaceutical compositions and their dermatological, gynecological and ophthalmic applications
Dec 15, 2009: Genocea Biosciences Awarded Grant For The Development Of Chlamydia Vaccines From The University Of Pittsburgh Medical Center’s Sexually Transmitted Infections Cooperative Research Center
Sep 13, 2007: Possible Vaccine Target For Chlamydia Identified
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Chlamydia Infections, H1 2015
Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Chlamydia Infections - Pipeline by Abera Bioscience AB, H1 2015
Chlamydia Infections - Pipeline by Adamis Pharmaceuticals Corporation, H1 2015
Chlamydia Infections - Pipeline by Big DNA Ltd., H1 2015
Chlamydia Infections - Pipeline by CEL-SCI Corporation, H1 2015
Chlamydia Infections - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015
Chlamydia Infections - Pipeline by Genocea Biosciences, Inc., H1 2015
Chlamydia Infections - Pipeline by Merck & Co., Inc., H1 2015
Chlamydia Infections - Pipeline by Osel Inc., H1 2015
Chlamydia Infections - Pipeline by Prokarium Ltd., H1 2015
Chlamydia Infections - Pipeline by QureTech Bio AB, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Chlamydia Infections Therapeutics - Recent Pipeline Updates, H1 2015
Chlamydia Infections - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Chlamydia Infections, H1 2015
Number of Products under Development for Chlamydia Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Abera Bioscience AB
Adamis Pharmaceuticals Corporation
Big DNA Ltd.
CEL-SCI Corporation
Foamix Pharmaceuticals Ltd.
Genocea Biosciences, Inc.
Merck & Co., Inc.
Osel Inc.
Prokarium Ltd.
QureTech Bio AB

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Amneal Pharmaceuticals LLC.
  • Amgen Inc.
  • LEO Laboratories Ltd.
  • Pfizer Inc.
  • Roche Diagnostics Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.